

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089788 A2

(51) International Patent Classification⁷: **A61K 31/22**,
47/26, 9/20

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP02/04891

(22) International Filing Date: 3 May 2002 (03.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0111077.4 4 May 2001 (04.05.2001) GB

(71) Applicant (*for all designated States except US*): BIO-CHEMIE GESELLSCHAFT M.B.H. [AT/AT]; A-6250 Kundl (AT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HEDGE, Deepak [IN/IN]; Flat No. 51, Bulding NO. H1, Awing, Shreerang Unit No. 24, Co-operative Housing Society, Behind Shreerang Society Bus Stop, Thane (W) 400 601 (IN). KULKARNI, Sushrut [IN/IN]; C002 Ganga Yamuna Apartments, Near Mohinder Singh School, Behind Ganesh Tower, Agra Road, Kalyan (W) 421 301 (IN).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/089788 A2

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A HMG-COA REDUCTASE INHIBITOR

(57) Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.

EXPRESS MAIL NO. EV545395338US
DOCKET NO. PC25264A

PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG-COA REDUCTASE INHIBITOR

The present invention relates to pharmaceutical compositions, comprising a HMG-CoA reductase inhibitor as an active ingredient.

- 5 Plasma cholesterol levels have been positively correlated with the incidence of clinical events associated with coronary heart disease (CHD). Thus, pharmacological interventions that reduce cholesterol levels in mammals may have a beneficial effect on CHD. In particular, decreased plasma low density lipoprotein (LDL) cholesterol levels are associated with decreased atherosclerosis and a decreased risk of CHD, and hypolipidemic agents used in
10 either monotherapy or combination therapy are effective at reducing plasma LDL cholesterol levels and the subsequent risk of CHD.

Cholesterol metabolism in mammals involves a series of pathways including cholesterol absorption in the small intestine, cholesterol biosynthesis in numerous tissues (primarily the liver and small intestine), bile acid biosynthesis in the liver and reabsorption in the small
15 intestine, synthesis of cholesterol-containing plasma lipoproteins by the liver and intestine, catabolism of the cholesterol-containing plasma lipoproteins by the liver and extrahepatic tissues and secretion of cholesterol and bile acids by the liver.

Cholesterol synthesis occurs in multiple tissues, but principally in the liver and the intestine. It is a multistep process starting from acetyl-coenzyme A catalyzed by a series of enzymes
20 including hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, HMG-CoA synthase, squalene synthetase, squalene epoxidase, squalene cyclase and lanosterol demethylase. Inhibition of catalysis of these enzymes or blocking HMG-CoA reductase gene expression is recognized as an effective means to reduce cholesterol biosynthesis and can lead to a reduction in cholesterol levels. Known HMG-CoA reductase inhibitors include statins, such
25 as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, mevastatin, rivastatin (cer(i)vastatin), pitavastatin (nisvastatin, itavastatin), rosuvastatin (visastatin), e.g. useful for the treatment of hypercholesterolemia.

HMG-CoA reductase inhibitors, such as statins however, may be unstable in acidic
30 environment, e.g. as described for pravastatin, for example in US5030447. To improve stability, in US5030447 it is suggested that pravastatin compositions should comprise one or more basifying agents to impart a desired pH of at least 9 to an aqueous dispersion of said composition, e.g. a composition comprising beside pravastatin one or more pharmaceutical

- 2 -

excipients, such as fillers, binders, disintegrants, lubricants. Although stability of HMG-CoA reductase inhibitors, such as statins, may be improved by combination of a basifying agent with a HMG-CoA reductase inhibitor-, such as statin-, -composition, a local alkaline environment created after dissolution of tablets in the stomach may have negative impact on gastric mucosa which may become a prominent problem e.g. in case of long time therapy.

We have now found a pharmaceutical composition comprising an HMG-CoA reductase inhibitor which is stable and which may have less negative impact on gastric mucosa than pharmaceutical compositions of prior art.

10

In one aspect the present invention provides a pharmaceutical composition comprising as an active ingredient a HMG-CoA reductase inhibitor; characterised in that said pharmaceutical composition comprises an amino sugar; e.g. as a pH adjusting (basifying) agent, e.g. and characterised in that an aqueous dispersion of said composition has a pH of at least 7.0, preferably at least 8.0; e.g. in case of pravastatin as a HMG-CoA reductase inhibitor a pH of 7.0 to 8.7, preferably 8.0 to 8.7, e.g. and wherein the HMG-CoA reductase inhibitor is stable, with the proviso that compositions

15

- comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivatives or HMG-CoA reductase inhibitors, and sugar derivatives, and

20

- comprising germs for a koji-making raw material and monacolin K, are excluded.

A composition comprising dehydroepiandrosterone (DHEA) and a desquamating agent selected from retinoids, acylated salicylic acid derivatives or HMG-CoA reductase inhibitors and sugar derivatives, is described in WO0126619. Such compositions are described to be usable in the cosmetic industry. A composition comprising germs (which germs comprises glucosamine) for a koji-making raw material, such as wheat or rice germs, and monacolin K (lovastatin) is described in JP2000106834. In JP2000106834 it is also described, that such compositions may be obtained by heating a mixture of wheat germs and rice germs with water, inoculating the mixture with *Monascus pilosus* IFO4520, culturing for 4 to 8 days, heating to 110°C for 20 minutes, drying the mixture obtained, e.g. to reduce the moisture content to 10% or less, and pulverizing.

25

30

According to the present invention a HMG-CoA reductase inhibitor includes, e.g. one or more, preferably one, HMG-CoA reductase inhibitor which is unstable in acidic environment, such as compounds as disclosed and cited in HMG-CoA reductase inhibitor patent filings, including statins. Such patent filings e.g. include US4231938 (including e.g. lovastatin);
5 EP0033538 (including e.g. simvastatin); GB2077264 (including e.g. pravastatin); EP0114027 (including e.g. fluvastatin); EP0247633 (including e.g. atorvastatin); US3983140 (including e.g. mevastatin); EP0491226 (including e.g. rivastatin; cer(i)vastatin); US5011930 (including e.g. pitavastatin, Nissan/Sankyo's nisvastatin (NK-104) or itavastatin); US5260440 (including e.g. rosuvastatin or visastatin (ZD-4522) of Shionogi-Astra/Zeneca); and US5753675
10 (including statins related to statins as described above); the content of said cited patent filings being introduced herein by reference. Preferably a HMG-CoA reductase inhibitor is selected from statins, such as lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, mevastatin, rivastatin (cer(i)vastatin), pitavastatin (nisvastatin, itavastatin), rosuvastatin (visastatin) or a related statin compound; more preferably from the group consisting of
15 lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, mevastatin, rivastatin (cer(i)vastatin), pitavastatin (nisvastatin, itavastatin) and rosuvastatin (visastatin), still more preferably pravastatin.

In another aspect the present invention provides a pharmaceutical composition according to
20 the present invention comprising as an active ingredient a statin, e.g. at least one, such as a statin selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, mevastatin, rivastatin (cer(i)vastatin), pitavastatin (nisvastatin, itavastatin) or rosuvastatin (visastatin), more preferably pravastatin.

25 A pharmaceutical composition according to the present invention may be obtained by mixing an HMG-CoA reductase inhibitor with an aminosugar. Preferably said aminosugar is an aminosugar which is able to adjust a pH of at least 7.0 of said composition in aqueous dispersion. Preferably said aminosugar is used as a pH-adjusting (basifying) agent. A preferred aminosugar according to the present present invention includes N-
30 methylglucamine.

The necessary amount of the aminosugar in respect with the amount of the HMG-CoA reductase inhibitor to obtain a pH of at least 7.0 in an aqueous dispersion may be critical and may be found by pre-testing. In case of N-methylglucamine as an aminosugar and in case of pravastatin as the HMG-CoA reductase inhibitor preferably the amount of the aminosugar in

- 4 -

respect with the amount of the HMG-CoA reductase inhibitor is 15% per weight and less, e.g. 6% to 15%.

- A pharmaceutical composition according to the present invention may comprise beside the
- 5 active ingredient and an aminosugar pharmaceutically acceptable excipient, e.g. one or more, such as excipient which is useful in the production of pharmaceutical compositions. Appropriate excipient may be found by pre-testing. Examples of such excipient include, e.g. one or more, filler and/or binder and/or disintegrant and/or lubricant, such as
- celluloses, e.g. including
 - 10 - powdered cellulose, e.g. as a filler;
 - microcrystalline cellulose, such as Avicel, e.g. including Avicel 102®; e.g. as a filler;
 - carboxymethylcelluloses, e.g. including croscarmellose sodium (crosslinked Na-carboxymethylcellulose), e.g. as a disintegrant;
 - hydroxyalkylcelluloses, e.g. including hydroxypropylcellulose, e.g. as a binder;
 - 15 - starches, e.g. including wheat starch, e.g. as a filler or as a binder;
 - polyvinylpyrrolidones, e.g. as a binder, e.g. including cross linked polyvinylpyrrolidones,
 - silicium (silicon) dioxides, e.g. including SiO₂ colloidal, e.g. as a disintegrant;
 - acrylic and methacrylic polymers, e.g. homo- and copolymers, such as the potassium salt of a low crosslinked carboxylic cation-exchange resin prepared from methacrylic acid and
 - 20 divinylbenzene, e.g. polyacrilin potassium, e.g. as a disintegrant;
 - lactose, e.g. as a filler;
 - Mg-stearate, Ca-stearate, e.g. as a lubricant;
 - Ca-sulphate, e.g. as a filler;
 - CAHPO₄, also known as calcium phosphate or dicalcium phosphate, e.g. as a filler;
 - 25 - MgAl-silicate, e.g. as a disintegrant.

- In another aspect the present invention provides a pharmaceutical composition according to the present invention and further comprising pharmaceutically acceptable excipient, e.g. comprising, e.g. selected from the group consisting of, one or more filler, and/or binder
- 30 and/or disintegrant and/or lubricant, e.g.
- a pharmaceutical composition consisting of
- a HMG-CoA reductase inhibitor as an active ingredient,
 - an aminosugar, and

- 5 -

- pharmaceutically acceptable excipient selected from the group consisting of one or more filler and/or binder and/or disintegrant and/or lubricant.

5 In a preferred embodiment of the present invention the pharmaceutical composition beside an HMG-CoA reductase inhibitor and an aminosugar further comprises one or more filler, binder, disintegrant and lubricant.

10 A pharmaceutical composition according to the present invention may be in any form, e.g. in solid form or in a liquid form, e.g. in the form of a suspension or emulsion for oral administration.

In another aspect the present invention provides a pharmaceutical composition according to the present invention which is in solid form.

15 Solid forms e.g. include granules, powders, tablets, preferably tablets. A solid form according to the present invention preferably include solid forms for oral administration.

20 In another aspect the present invention provides a pharmaceutical composition according to the present invention which is in in the form of a tablet, e.g. for oral administration.

A tablet according to the present invention includes a non-dispersible and a dispersible tablet. A dispersible tablet is understood to include a tablet which forms a (homogenous) dispersion in aqueous solvent, e.g. resulting in an emulsion or suspension for oral administration. A preferred HMG-CoA reductase inhibitor includes pravastatin, e.g. in the form of a sodium salt.

25 A tablet according to the present invention includes a tablet wherein the amount of the aminosugar is 5.0% and less of the total tablet weight, e.g. 2.0% and less, such as 0.5% to 5.0% and wherein the HMG-CoA reductase inhibitor is pravastatin, e.g. in the form of a sodium salt.

30 In a preferred embodiment of the present invention a pharmaceutical composition according to the present invention which is in the form of a tablet, e.g. for oral administration, may be prepared as follows:

An HMG-CoA reductase inhibitor, such as a statin, e.g. pravastatin, such as pravastatin in the form of a sodium salt, may be mixed with filler and/or binder. The mixture obtained may be granulated with water. Alternatively the HMG-CoA reductase inhibitor may be mixed with filler and/or binder and the mixture obtained may be granulated with water in which one or
5 more, preferably one, aminosugar as a pH-adjusting (basifying) agent, is dissolved. Granulate obtained may be dried and optionally processed through a sieve, preferably a sieve having a pore size between 1.0 to 3.0 mm, such as 2.0 mm. Granulate obtained may be optionally mixed with further aminosugar as a pH-adjusting (basifying) agent, in the case that during granulation aminosugar was already present, and in the case that during
10 granulation no aminosugar was present, granulate obtained is mixed with aminosugar as a pH-adjusting (basifying) agent. A mixture obtained may be compressed to obtain tablets.

Preferred dosage units include such which are normally useful, e.g. which are known to be useful, for a specific HMG-CoA reductase inhibitor. In the case that pravastatin sodium is
15 used as a HMG-CoA reductase inhibitor most preferably one tablet contains 10, 20 or 40 mg of pravastatin sodium.

In another aspect the present invention provides a tablet for oral administration according to the present invention comprising, e.g. consisting of, pravastatin in the form of a sodium salt,
20 and further comprising filler and/or binder and/or disintegrant and/or lubricant; and aminosugar; e.g. as a pH adjusting (basifying) agent, in such an amount, that a dispersion of said tablet in water has a pH of 7.0 to 8.7, preferably of 8.0 to 8.7.

In another aspect the present invention provides a tablet for oral administration comprising,
25 e.g. consisting of, pravastatin in the form of a sodium salt, filler, binder, disintegrant, lubricant and aminosugar; e.g. as a pH adjusting (basifying) agent, in such an amount, that a dispersion of said tablet in water has a pH of 7.0 to 8.7, preferably of 8.0 to 8.7.

In another aspect the present invention provides a tablet according to the present invention,
30 comprising, e.g. consisting of pravastatin in the form of a sodium salt as an active ingredient, and - lactose, microcrystalline cellulose, polyvinylpyrrolidone, croscarmellose sodium, and Mg-stearate, or

- 7 -

- dicalcium hydrogen phosphate, powdered cellulose, hydroxypropylcellulose, SiO₂, Ca-stearate and the potassium salt of a low crosslinked carboxylic cation-exchange resin prepared from methacrylic acid and divinylbenzene, or
 - dicalcium hydrogen phosphate, powdered cellulose, wheat starch, SiO₂, Ca-stearate and the potassium salt of a low crosslinked carboxylic cation-exchange resin prepared from methacrylic acid and divinylbenzene,
- and
- N-Methyl glucamine as a pH-adjusting (basifying) agent in such an amount, that a dispersion of said tablet in water has a pH of 7.0 to 8.7.
- In another aspect the present invention provides a process of the production of a tablet for oral administration comprising as an active ingredient an HMG-CoA reductase inhibitor; which process comprises the steps
- a. mixing an HMG-CoA reductase inhibitor with filler and/or binder, e.g. with filler and binder,
 - b. granulating the mixture obtained in step a., e.g. with water as a granulation liquid, or with water wherein aminosugar is dissolved, e.g. in an amount, that a dispersion of a tablet for oral administration obtained in step f. in water has a pH of at least 7.0; or has a pH of below 7.0, to obtain a granulate, e.g. granulated particles containing an HMG-CoA reductase inhibitor and filler and/or binder, and optionally aminosugar,
 - c. drying a granulate obtained in step b.,
 - d. optionally processing a granulate obtained in step c. through a sieve,
 - e. in case that no aminosugar was present in step b., mixing granulate obtained in step c. or step d. with aminosugar as a pH-adjusting (basifying) agent in such an amount, that a dispersion of said tablet for oral administration in water has a pH of at least 7.0, and, if aminosugar was present in step a., optionally mixing granulate obtained in step c. or step d. with aminosugar as a pH-adjusting (basifying) agent in such an amount, that a dispersion of said tablet for oral administration in water has a pH of at least 7.0, e.g. in the case that the amount of aminosugar present in step b. was not sufficient to adjust a pH of at least 7.0; and optionally, e.g. preferably, with disintegrant and/or lubricant, e.g. disintegrant and lubricant; and
 - f. compressing the mixture obtained in step e. to obtain tablets, e.g. useful for oral administration.

In the case that pravastatin sodium is used as an HMG-CoA reductase inhibitor preferably a tablet contains 10, 20 or 40 mg of pravastatin sodium, e.g. and a dispersion of said tablet for oral administration in water has a pH of 7.0 to 8.7, preferably 8.0 to 8.7.

- 5 In a dispersion in water of a compressed tablet according to the present invention the HMG-CoA reductase inhibitor may be stable under normal environment humidity conditions for 1 months and more.

Examples for the production of tablets

As an active ingredient pravastatin in the form of a sodium salt is used.

- The active ingredient is mixed with filler(s) and binder(s) and the mixture obtained is granulated in a wet granulation process with water. The granulate obtained is dried and
- 5 processed through a sieve having a pore size of 2.0 mm. The granulated particles obtained are mixed with disintegrant(s), lubricant(s) and an aminosugar, or, alternatively, the active ingredient is mixed with filler(s) and binder(s) and the mixture obtained is granulated in a wet granulation process with water in which an aminosugar has been dissolved. The granulate obtained is dried and processed through a sieve having a pore size of 2.0 mm. The
- 10 granulated particles obtained are mixed with disintegrant(s) and lubricant(s).

The mixture obtained according to either process is compressed into tablets comprising 10, 20 or 40 mg of pravastatin in the form of a sodium salt.

- 15 Ingredients of 3 different tablet compositions obtained (in % per weight of one tablet) according to both procedures described above are as set out in TABLE 1 below:

TABLE 1

	Preparation 1	Preparation 2	Preparation 3
Pravastatin in the form of a sodium salt	10.00	10.00	10.00
Lactose as a filler	68.20	-	-
Microcrystalline cellulose *) as a filler	13.50	-	-
Dicalcium hydrogen phosphate as a filler	-	65.00	65.00
Powdered cellulose as a filler	-	17.00	17.00
Polyvinylpyrrolidone as a binder	0.50	-	-
Hydroxypropylcellulose as a binder	-	1.00	-
Wheat starch as a binder	-	-	1.00
Croscarmellose sodium as a disintegrant	6.00		
SiO ₂ colloidal as a disintegrant	-	2.50	2.50
Polyacrilin***) potassium as a disintegrant	-	2.50	2.50

	Preparation 1	Preparation 2	Preparation 3
Mg-stearate as a lubricant	1.00	-	-
Ca-stearate as a lubricant	-	1.00	1.00
Meglumine**) as a pH adjusting agent	0.80	1.00	1.00

*) Avicel pH 102

**) N-Methyl glucamine

***) Potassium salt of a low crosslinked carboxylic cation-exchange resin prepared from methacrylic acid and divinylbenzene.

5

The pH of an aqueous dispersion of a tablet obtained as described in that example and comprising the ingredients of a Preparation 1, Preparation 2 or Preparation 3 as set out in TABLE 1 above, is determined and is between 8.0 and 8.7. Preparation 1, Preparation 2 and Preparation 3 is stable for more than 1 month under normal environment humidity

10 conditions.

Patent Claims

1. A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor; characterised in that said composition comprises an aminosugar,
5 with the proviso that compositions
- comprising dehydroepiandrosterone (DHEA), a desquamating agent selected from retinoids, acylated salicylic acid derivatives or HMG-CoA reductase inhibitors, and sugar derivatives, and
- comprising germs for a koji-making raw material and monacolin K,
10 are excluded.
2. A pharmaceutical composition according to claim 1, further comprising pharmaceutically acceptable excipient.
- 15 3. A pharmaceutical composition according to claim 2, wherein pharmaceutically acceptable excipient is selected from the group comprising one or more filler and/or binder and/or disintegrant and/or lubricant..
4. A pharmaceutical composition consisting of
20 - a HMG-CoA reductase inhibitor as an active ingredient,
- an aminosugar, and
- pharmaceutically acceptable excipient selected from one or more filler and/or binder and/or disintegrant and/or lubricant.
- 25 5. A pharmaceutical composition according to any one of claims 2 to 4, wherein the pharmaceutically acceptable excipient comprises one or more filler, binder, disintegrant and lubricant.
6. A pharmaceutical composition according to any one of claims 1 to 5, wherein the HMG-
30 CoA reductase inhibitor is a statin.
7. A pharmaceutical composition according to claim 6, wherein the statin is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin,

- 12 -

mevastatin, rivastatin (cer(i)vastatin), pitavastatin (nisvastatin, itavastatin) and
rosuvastatin (visastatin).

- 5 8. A pharmaceutical composition according to any one of claims 6 or 7, wherein the statin
is pravastatin.
9. A pharmaceutical composition according to any one of claims 1 to 8 which is in solid
form.
- 10 10. A pharmaceutical composition according to claim 9 which is in the form of a tablet.
11. A tablet for oral administration consisting of pravastatin in the form of a sodium salt, one
or more filler, binder, disintegrant and/or lubricant, and aminosugar as a pH-adjusting
(basifying) agent in such an amount, that a dispersion of said tablet in water has a pH of
15 7.0 to 8.7.
12. A tablet according to claim 11 consisting of
pravastatin in the form of a sodium salt as an active ingredient, and
- lactose, microcrystalline cellulose, polyvinylpyrrolidone, croscarmellose sodium, and
20 Mg-stearate, or
- dicalcium hydrogen phosphate, powdered cellulose, hydroxypropylcellulose, SiO₂, Ca-
stearate and the potassium salt of a low crosslinked carboxylic cation-exchange resin
prepared from methacrylic acid and divinylbenzene, or
- dicalcium hydrogen phosphate, powdered cellulose, wheat starch, SiO₂, Ca-stearate
25 and the potassium salt of a low crosslinked carboxylic cation-exchange resin prepared
from methacrylic acid and divinylbenzene,
and
N-Methyl glucamine as a pH-adjusting (basifying) agent in such an amount, that a
dispersion of said tablet in water has a pH of 7.0 to 8.7.

30

35

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089788 A3

(51) International Patent Classification⁷: **A61K 31/22,**
47/26, 9/20

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP02/04891

(22) International Filing Date: 3 May 2002 (03.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0111077.4 4 May 2001 (04.05.2001) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(71) Applicant (*for all designated States except US*): BIO-CHEMIE GESELLSCHAFT M.B.H. [AT/AT]; A-6250 Kundl (AT).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HEDGE, Deepak [IN/IN]; Flat No. 51, Bulding NO. H1, Awing, Shreerang Unit No. 24, Co-operative Housing Society, Behind Shreerang Society Bus Stop, Thane (W) 400 601 (IN). KULKARNI, Sushrut [IN/IN]; C002 Ganga Yamuna Apartments, Near Mohinder Singh School, Behind Ganesh Tower, Agra Road, Kalyan (W) 421 301 (IN).

(88) Date of publication of the international search report:
12 December 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/089788 A3

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING A HMG-COA REDUCTASE INHIBITOR

(57) Abstract: A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/EP 02/04891

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/22 A61K47/26 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, PASCAL, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 35425 A (LEK TOVARNA FARMACEVTSKIH ;KER & CCARON (SI)) 22 June 2000 (2000-06-22) page 6, line 1 -page 10, line 31; claims 31-38; examples 1-5 ---	6-12
Y	EP 0 547 000 A (HOECHST AG) 30 June 1982 (1982-06-30) claims 1-11 ---	6,7,9,10
Y	KIBBE AH: "Handbook of Pharmaceutical Excipients", AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, USA, 2000 XP002206082 page 332 -page 333 --- -/--	6-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

29 July 2002

Date of mailing of the international search report

09/08/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zimmer, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 02/04891

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 030 447 A (JOSHI YATINDRA M ET AL) 9 July 1991 (1991-07-09) cited in the application column 1, line 37 -column 2, line 4; examples 1-9 ---	6-12
A	WO 94 16693 A (WARNER LAMBERT CO) 4 August 1994 (1994-08-04) the whole document ---	6-12
P,X	WO 01 93860 A (LEK TOVARNA FARMACEVTSKIH) 13 December 2001 (2001-12-13) page 11, line 30 -page 12, line 25; claims 1-18 -----	6-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 02/04891

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0035425	A	22-06-2000	SI 20109 A	30-06-2000
			AU 6360899 A	03-07-2000
			BG 105559 A	31-12-2001
			CN 1330538 T	09-01-2002
			CZ 20011727 A3	12-09-2001
			EP 1148872 A1	31-10-2001
			WO 0035425 A1	22-06-2000
			PL 347686 A1	22-04-2002
			SK 8092001 A3	08-10-2001
			TR 200101235 T2	22-10-2001
EP 0547000	A	16-06-1993	AT 401872 B	27-12-1996
			AT 190595 A	15-05-1996
			AT 401870 B	27-12-1996
			AT 244992 A	15-05-1996
			AU 661075 B2	13-07-1995
			AU 3006992 A	17-06-1993
			CA 2085037 A1	13-06-1993
			CH 684309 A5	31-08-1994
			CZ 9203633 A3	15-09-1993
			CY 1994 A	05-09-1997
			DE 4240430 A1	17-06-1993
			DK 547000 T3	26-06-2000
			EP 0547000 A1	16-06-1993
			ES 2142819 T3	01-05-2000
			FI 925615 A	13-06-1993
			FR 2684876 A1	18-06-1993
			GB 2262229 A ,B	16-06-1993
			GR 3032929 T3	31-07-2000
			HK 25597 A	06-03-1997
			HU 63328 A2	30-08-1993
			IL 104041 A	27-12-1998
			IT 1256698 B	12-12-1995
			JP 2774037 B2	09-07-1998
			JP 5246844 A	24-09-1993
			KR 253824 B1	01-05-2000
			LU 88201 A1	09-09-1994
			MX 9207152 A1	01-07-1993
			NO 924768 A	14-06-1993
			NZ 245421 A	27-11-1995
			NZ 270729 A	27-11-1995
			PT 547000 T	30-06-2000
			RO 111542 B1	29-11-1996
			RU 2121835 C1	20-11-1998
			SK 363392 A3	09-11-1994
			US 5356896 A	18-10-1994
			ZA 9209642 A	13-06-1994
US 5030447	A	09-07-1991	AT 79030 T	15-08-1992
			AU 3027689 A	05-10-1989
			CA 1323836 A1	02-11-1993
			CN 1036508 A ,B	25-10-1989
			CY 1675 A	10-10-1993
			DE 68902344 D1	10-09-1992
			DE 68902344 T2	07-01-1993
			DK 155689 A	01-10-1989
			EP 0336298 A1	11-10-1989
			HK 40093 A	30-04-1993

INTERNATIONAL SEARCH REPORT

ation on patent family members

Internat Application No

PCT/EP 02/04891

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5030447	A	IE 62956 B	08-03-1995
		JP 2006406 A	10-01-1990
		JP 2935220 B2	16-08-1999
		NZ 228076 A	26-04-1991
		SG 107292 G	24-12-1992
		US 5180589 A	19-01-1993
		ZA 8901424 A	25-10-1989
WO 9416693	A 04-08-1994	AT 178794 T	15-04-1999
		CA 2150372 A1	04-08-1994
		DE 69324504 D1	20-05-1999
		DE 69324504 T2	26-08-1999
		DK 680320 T3	25-10-1999
		EP 0680320 A1	08-11-1995
		ES 2133158 T3	01-09-1999
		GR 3030359 T3	30-09-1999
		JP 3254219 B2	04-02-2002
		JP 8505640 T	18-06-1996
		MX 9400281 A1	29-07-1994
		SG 45369 A1	16-10-1998
		WO 9416693 A1	04-08-1994
		US 5686104 A	11-11-1997
		US 6126971 A	03-10-2000
WO 0193860	A 13-12-2001	WO 0193860 A1	13-12-2001
		AU 4943400 A	17-12-2001